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Abstract
Background: Fertility-sparing surgery for patients with borderline ovarian tumors (BOTs) is still controversial. This
study aimed to evaluate the oncological safety and fertility benefits in conservative surgery,as well as efficiency of
surgical procedures and approaches.
Results: In total 122 patients with BOTs, four types of fertility-sparing surgery were performed: unilateral adnexectomy
(UA, n = 47), unilateral cystectomy (UC, n = 59), unilateral adnexectomy + contralateral cystectomy (UA + CC, n = 7) and
bilateral cystectomy (BC, n = 9). Fifty-two (42.6 %) patients had undergone laparoscopy, while 70 (57.4 %) had
undergone laparotomy. After a median follow-up of 58.0 months, eight patients (6.6 %) relapsed in average
of 25.9 months. Only one patient progressed to invasive cancer. None died within our observational period.
Univariate analysis showed that patients with elevated CA125, bilateral tumors, extra-ovary tumor or mucinous
type tended to replase in shorter time (p < 0.05). Among all cases, 45 patients attempted to conceive and 34
(75.6 %) patients had successful pregnancy.
The recurrence rates were successively increased (2.1 %, 6.8 %, 14.3 %, and 22.2 %), the recurrence interval
were shortened (48.0, 25.3, 26.0 and 21.2 months) and the subsequent fertility rates were 76.9 %, 77.3 %,
66.7 % and 71.4 % in UA, UC, UA + CC, and BC groups, respectively. As for surgical approaches, three patients
(5.8 %) relapsed in 26.3 months in the laparoscopy group and five (7.1 %) in 25.5 months in the laparotomy
group. The subsequent fertility rate was higher in laparoscopy group (88.9 %) than in laparotomy group (66.7 %).
In our study, 38 patients underwent staging surgery. Two patients (5.3 %) recurrent in average of 21.0 months,
and the subsequent pregnancy rate of staging surgery group was 61.5 %. Twelve patients received adjuvant
chemotherapy but they didn’t get any benefit from it, both in term of recurrence (8.3 %, 26.0 months) and
subsequent pregnancy rate (75.5 %).
Conclusion: Fertility-sparing surgery is safe and beneficial for most young BOTs. UA through laparoscopy should
be recommended as the first choice. To the patients with bilateral tumors, elevated CA125, extra-ovary tumor or
mucinous type, conservative surgery should be carefully chosen and subsequent pregnancy should be attempted
in short term. In addition, the benefit of comprehensive surgical staging is to be further investigated and adjuvant
chemotherapy is not recommended.
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Background
Borderline ovarian tumors (BOTs) are defined as an epi-
thelial ovarian tumor exhibiting an atypical epithelial
proliferation without destructive stromal invasion. They
account for 10–20 % of all ovarian epithelial tumors,
with an incidence of 1.8–4.8 per 100,000 women per
year [1, 2]. The International Federation of Gynecology
and Obstetrics (FIGO) acknowledged BOTs as a separate
entity in 1961 and the World Health Organization
(WHO) recognized the classification in 1973. Three
terms are currently used to refer these tumors: border-
line tumor, tumor of low malignant potential, and atyp-
ical proliferative tumor. Compared to invasive epithelial
ovarian cancers, BOTs are typically present in younger
women, primarily diagnosed at earlier stages, and result
in more favorable prognosis [3, 4]. Over the past several
decades, the incidence of BOT has been increased, and
surgical therapy has shifted from a radical approach to
more conservative treatment. Recent studies have indi-
cated that the fertility-sparing treatment with BOTs is
well tolerated and able to permit future pregnancy [5, 6].
However, the fertility sparing treatment may increase the
risk of relapse and sometimes lead to death [7–9].
Therefore, oncological safety must always be balanced at
the same time. There was no randomized clinical trial to
concern the prognostic factors of recurrence and subse-
quent fertility rate in different fertility sparing therapeutic
strategies. Therefore, the optimal clinical strategies for
young patients with BOT are often discussed. The purpose
of this study is to analyze the oncological safety of fertility-
sparing surgery, the efficacy of different surgical procedures
and approaches, as well as adjuvant chemotherapy on the
recurrence rate and reproductive outcomes.
Methods
The retrospective study enrolled 122 patients with BOTs
who underwent fertility-sparing surgery from Jan. 1st
2003 to Dec. 31st 2010 in Obstetrics and Gynecology
Hospital of Fudan University. Information was collected
by reviewing medical files, making systematic phone
calls or performing out-patient clinic interviews. Recur-
rence and pregnancy information were collected after at
least 2 years’ follow-up (until December 31st, 2012). Pa-
tients were scheduled for a pelvic examination, pelvic
ultrasound examination (CT or MRI scan if necessary),
and CA125 measurement every 3 months during the
first year after surgery, and then every 6 months for
2 years and then annually follow up.
In addition to tumor’s FIGO stage and pathology type,
whether a BOTs patient should receive conservative
Fig 1 Recurrence free survival rates after fertility-sparing surgeries. a Comparison of recurrence free survival rates between different surgical
procedures (adnexectomy and cystectomy-included). b Comparison of recurrence free survival rates in unilateral BOT patients(UA and UC).
c Comparison of recurrence free survival rates in bilateral BOT patients (UA + CC and BC). d Comparison of recurrence free survival rates between
different surgical approaches (laparotomy and laparoscopy)
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treatment depended on the patient’s age, wish to preserve
fertility, prior surgeries received and general health condi-
tions. These criteria were fully evaluated by experienced
gynecologic oncologists before surgery. Fertility-sparing
surgery was defined as a procedure that preserved the
uterus and at least part of one ovary with the goal of fertil-
ity preservation. Histological typing of tumor was per-
formed according to the WHO 2003 system, and tumor
staging system was based on the FIGO 2006 system. All
tumor specimens were reviewed by at least two experi-
enced pathology specialists.
All statistical analyses were conducted with the Statis-
tical Package for Social Sciences software, version 16.0
(SPSS 16.0, Chicago, IL, USA). Categorical variables
were assessed using the Chi-squared test or the Fisher
exact test, and quantitative variables were compared
using Student’s T-test or the Mann-Whitney U-test. The
survival curves were drawn using the Kaplan-Meier
method, and significant differences between the curves
were assessed with the long-rank test. A p value of <0.05
was considered to be statistically significant.
Results
Patient characteristics
A total of 122 patients with BOTs underwent conservative
surgery from Jan. 1st 2003 to Dec. 31st 2010 in the Obstet-
rics and Gynecology Hospital of Fudan University were
reviewed in this study. The demographic and clinicopath-
ologic characteristics of enrolled patients were shown in
Table 1. The median age of these young patients was
30.2 years (range, 11–49 years) and 79 patients (64.8 %)
were nulliparous. The serum level of CA125 was tested
preoperatively in 83 patients and elevated in only 29 cases
(34.9 %). Majority of patients (n = 87) complained abdom-
inal masses for their first visit, then abdominal pain and
enlarged abdominal perimeters. There were 111 patients
diagnosed at early stage, of them 70.5 % cases (n = 86)
were at stage Ia. The average diameter of BOTs was
10.5 cm. Tumors were limited inner-ovary in 94 patients,
while extra-ovary in the other 28 cases. BOTs were unilat-
eral in 86.9 % patients (n = 106) and the most common
pathology type was serous (SBOTs) (n = 64, 52.5 %), then
mucinous (MBOTs) (n = 51, 41.8 %).














Total number 122 114 (93.4 %) 8 (6.6 %) N/A 25.9 11 (24.4 %) 34 (75.6 %)
Age (y, mean ± SD) 30.2 ± 7.3 30.3 ± 7.3 29.1 ± 6.8 0.65 N/A 29.7 ± 4.4 27.6 ± 4.5 0.19
Parity
Multiparous 43 (35.2 %) N/A N/A N/A
Nulliparous 79 (64.8 %)
Tumor marker CA125 (tested) 83
Normal 54 (65.1 %) 50 (92.6 %) 4 (7.4 %) 0.69 25.7 0.00 N/A
Elevated 29 (34.9 %) 26 (89.7 %) 3 (10.3 %) 22.4
Lesion location
Inner-ovary 94 (77.0 %) 89 (94.7 %) 5 (5.3 %) 0.38 31.9 0.00 6 (18.8 %) 26 (81.2 %) 0.25
Extra-ovary 28 (23.0 %) 25 (89.3 %) 3 (10.7 %) 22.1 5 (38.5 %) 8 (61.5 %)
Lesion size (cm ± SD) 10.5 ± 7.0 10.4 ± 7.0 12.0 ± 7.9 0.59 N/A 8.7 ± 4.7 10.1 ± 6.8 0.52
Lesion lateral
Unilateral 106 (86.9 %) 101 (95.3 %) 5 (4.7 %) 0.07 33.2 0.00 8 (22.9 %) 27 (77.1 %) 0.69
Bilateral 16 (13.1 %) 13 (81.3 %) 3 (18.7 %) 23.0 3 (30.0 %) 7 (70.0 %)
FIGO stage
Stage I 111 (91.0 %) 104 (93.7 %) 7 (6.3 %) 0.54 30.4 N/A 8 (20.0 %) 32 (80.0 %) 0.09
> = Stage II 11 (9.0 %) 10 (90.9 %) 1 (9.1 %) 26.0 3 (60.0 %) 2 (40.0 %)
Pathology types
Endometriod 5 (4.1 %) 4 (80.0 %) 1 (20.0 %) 0.29 21.0 N/A 0 3 (100 %) 0.57
Serous and/or mucious 117 (95.9 %) 110 (94.0 %) 7 (6.0 %) 30.8 11 (26.2 %) 31 (73.8 %)
Serous 64 (52.5 %) 60 (93.8 %) 4 (6.2 %) 1.00 35.9 0.00 9 (32.1 %) 19 (67.9 %) 0.45
Mucinous 51 (41.8 %) 48 (94.1 %) 3 (5.9 %) 18.5 2 (15.4 %) 11 (84.6 %)
Serous and mucinous 2 (1.6 %) 2 0 N/A 0 1 N/A
Abbreviations: BOT borderline ovarian tumor FIGO, the International Federation of Gynecology and Obstetrics, N/A not applicable
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Univariate analysis showed that bilateral tumor associ-
ates with higher recurrence rate in compare with that of
unilateral tumor (18.7 % vs. 6.6 %, p = 0.07). Patients with
elevated CA125, bilateral tumors, extra-ovary tumor or
mucinous type tended to replase in shorter time (p < 0.05)
Fertility-sparing surgery
Adnexectomy & cystectomy
Along with the development of minimally invasive surgical
techniques, National Comprehensive Cancer Network
(NCCN) kept updating the guidelines for BOTs patients’
management, and we also followed the updates in our clin-
ical practice in our hospital (as showed in Tables 2 and 3).
Until the end of our study, the average observation period
was 65.1 months in adnexectomy group and 53.4 months
in cystectomy-included groups, respectively. It indicated
that young women with BOTs tended to choose even more
conservative treatment in recent years Compared with
adnexectomy group, the recurrence rate was higher and
the recurrence interval was shorter in cystectomy-included
group, though the difference did not reach statistical
significance (9.3 % vs 2.1 % p = 0.15, 48.0 months vs
22.7 months, N/A)(as shown in Fig. 1). Our study showed
that only one patient progressed to invasive cancer but
none died within our observation period. On the other
hand, both surgical strategies provide good subsequent preg-
nancy rate (up to 75.0 %) for the BOTs patients. Until the
end of our study, there was no abnormal fetus delivered.
Unilateral adnexectomy vs Unilateral cystectomy
There were 106 cases with unilateral BOTs in this study,
47 women underwent UA and 59 underwent UC. The op-
eration duration was shorter in the UC group than in the
UA group (p = 0.06). However, more patients replased in
shorter time in UC group, though this difference was not
statistically significant (6.8 % vs 2.1 %, p > 0.05, 48.0 vs
22.8 months, N/A) (as shown in Fig. 1). The operational
blood loss, total duration of hospitalization and days of
antibiotic use were similar (p > 0.05), and 85 patients in
these two groups still had regular menstruation after treat-
ment. Twenty-seven pregnancies were achieved in 35
cases with unilateral BOTs, including 10 (76.9 %) in the
UA group and 17 (77.3 %) in the UC group.
Unilateral adnexectomy + contralateral cystectomy vs
Bilateral cystectomy
Among 16 patients with bilateral BOTs, seven under-
went UA + CC, and nine underwent BC. The operation
durations, hospitalization days and operational blood
loss were similar between the two groups, but the days
of antibiotic using were significantly shorter in BC group
(p < 0.05). Compared to cases with unilateral BOTs, the
recurrence rate was higher and the replase interval was
shorter in patients with bilateral tumors, especially in
BC group. Though the difference was not statistically
significant between the BC and UC + CC groups
(22.2 % vs 14.3 %,21 vs 26 months, p > 0.05)(as shown
in Fig. 1). Patients in UA + CC group were more likely
to have irregular menstruation and climacteric symp-
toms after surgery Accordingly, the subsequent fertility
rates were 66.7 % (2/3) in UA + CC group and 71.4 %
(5/7) in BC group, respectively. However, the overall
pregnancy rate was still satisfying in patients with bilat-
eral tumors after conservative surgery.
Laparoscopy vs Laparotomy
In this study of 122 cases with BOTs, 52 patients
underwent laparoscopy, and 70 patients underwent
laparotomy. Though the operation duration was simi-
lar between two groups, the operational blood loss,
duration of hospitalization and days of antibiotic using
were much lower in laparoscopy group. As for recur-
rence results, three of 52 patients in laparoscopy
group and five of 70 patients in laparotomy group














Total number 122 114 (93.4 %) 8 (6.6 %) N/A 25.9 11 (24.4 %) 34 (75.6 %)
Surgical procedures
Adnexectomy 47 46 (97.9 %) 1 (2.1 %) 0.15 48.0 N/A 3 (23.1 %) 10 (76.9 %) 1.00
Cystectomy inclued 75 68 (91.7 %) 7 (9.3 %) 22.7 8 (25.0 %) 24 (75.0 %)
Staging surgery
No 84 (68.9 %) 78 (92.9 %) 6 (7.1 %) 1.00 32.1 N/A 6 (18.7 %) 26 (81.3 %) 0.08
Yes 38 (31.1 %) 36 (94.7 %) 2 (5.3 %) 21.0 6 (46.2 %) 7 (53.8 %)
Adjuvant chemotherapy 0.58 1.00
Yes 12 (9.8 %) 11 (91.7 %) 1 (8.3 %) 26.0 N/A 2 (25.0 %) 6 (75 %)
No 110 (90.2 %) 103 (93.6 %) 7 (6.4 %) 30.4 9 (24.3 %) 28 (75.7 %)
Cystectomy-inclued group included UC,BC,UA + CC
Abbreviations: N/A not applicable
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(5.8 % vs 7.1 %, p > 0.05) were relapsed in average 26.3
and 25.5 months respectively (as shown in Fig.1).
What’s more, the status of menstruation after treat-
ment was similar between these two groups. However,
11.1 % cases were confronted with infertility in lapar-
oscopy group and that rate was up to 33.33 % in the
laparotomy group, indicating a tendency of higher in-
fertility rate in the latter group, but the difference was
not statistically significant (P > 0.05).
Staging surgery
In our study, 38 patients underwent staging surgery,
while the remaining 84 patients did not. As for the spe-
cific staging procedures, omentum resection/biopsy, ap-
pendectomy, lymph node dissection/biopsy, peritoneal
biopsy and contralateral ovary biopsy were performed in
18, 7, 7, 9, and 19 patients, respectively. The pathological
positive results were only found in one patient done by
omentum resection and two patients done by lymph
node dissection. Though staging surgery to some extend
advanced the FIGO stage, the recurrence results wasn’t
improved much by it (P > 0.05). Two patients (5.3 %) in
the staging surgery group experienced disease relapse in
21.0 months, while six patients (7.1 %) in 32.1 months in
the non-staging surgery group. As for fertility preserva-
tion, the fertility rate was 53.8 % in the staging surgery
group and that rate ran up to 81.3 % in the non-staging
group. Though the difference was not statistically
significant (p > 0.05), it still indicated an obvious declin-
ation of fertility ability in staging surgery group.
Adjuvant chemotherapy
Most patients in our study hadn’t received chemother-
apy after conservative treatment. Only 12 patients
underwent adjuvant chemotherapy and most of them
were in late FIGO stage (≥Ic) or with invasive implants.
But the results showed that they didn’t seem to get any
benefit from it both in recurrence and pregnancy. There
were 8.3 % patients, who received adjuvant chemother-
apy, got disease recurred after 26.0 months. Accordingly,
6.4 % cases without chemotherapy had disease recurrence
in 30.4 months after conservative treatment. What’s more,
the fertility outcomes were nearly the same in patients
with or without adjuvant chemotherapy and both of them
were about 75.0 % successful pregnancy rate.
Discussion
As long-term survival rates of ovarian cancer patients
improved and advanced assisted reproductive technol-
ogy developed, there is increased interest in fertility-
sparing surgery among young women with ovarian
tumors [10, 11]. In literatures, the recurrence rate of
BOTs varies between 0 and 25 %, with a 1–3 % invasive
relapse rate [12, 13]. A systematic review [14] of 923
patients from 19 studies calculated that the recurrence
rate was 16 %, with five disease-related deaths, and a
Table 3 The operation situation and results of recurrence and pregnancy in different fertility-sparing surgery groups
Clinical characteristics Surgical procedure p value Surgical procedure p value Surgical approach p value
UA UC UA + CC BC Laparotomy Laparocsopy
Total number (n) 47 59 7 9 70 52
Operation duration (min, mean ± SD) 106.8 ± 49.8 90.6 ± 38.8 0.06 194.6 ± 70.4 165.5 ± 82.0 0.46 104.7 ± 47.4 113.3 ± 66.8 0.43
Intro-operation blood loss
(ml, mean ± SD)
91.7 ± 85.1 105.7 ± 152.8 0.58 202.9 ± 139.8 144.4 ± 72.6 0.19 124.9 ± 151.9 86.7 ± 76.6 0.07
Hospitalization days (days, mean ± SD) 10.5 ± 4.2 9.6 ± 3.5 0.19 14.7 ± 5.6 14.8 ± 5.7 0.98 11.8 ± 4.5 9.1 ± 3.6 0.00
Days of antibiotic using
(days, mean ± SD)
3.2 ± 1.1 3.2 ± 0.9 0.8 4.1 ± 0.9 3.1 ± 0.3 0.01 3.4 ± 1.0 3.0 ± 0.7 0.01
Menstrual status (n, %)
Regular 38 (80.9 %) 47 (79.7 %) 0.88 4 (57.1 %) 7 (77.8 %) 1.00 55 (78.6 %) 41 (78.8 %) 0.97
Irregular 9 (19.1 %) 12 (20.3 %) 3 (42.9 %) 2 (22.2 %) 15 (21.4 %) 11 (21.2 %)
Climacteric symptom (n, %) 5 (10.6 %) 4 (6.8 %) 0.51 2 (28.6 %) 0 0.18 8 (11.4 %) 3 (5.8 %) 0.35
Relapse (n, %) 1 (2.1 %) 4 (6.8 %) 0.38 1 (14.3 %) 2 (22.2 %) 1.00 5 (7.1 %) 3 (5.8 %) 1.00
Recurrence interval (m, mean ± SD) 48.0 22.8 ± 8.8 N/A 26.0 21.0 N/A 25.5 ± 15.3 26.3 ± 7.6 0.92
Invasive recurrence (n) 0 1 (1.7 %) N/A 0 0 N/A 1 (1.4 %) 0 N/A
Disease related death (n) 0 0 N/A 0 0 N/A 0 0 N/A
Patients desired to get pregnancy (n, %) 13 22 3 7 27 18
Pregnancy 10 (76.9 %) 17 (77.3 %) 1.00 2 (66.7 %) 5 (71.4 %) 0.57 18 (66.7 %) 16 (88.9 %) 0.16
Inferterlity 3 (23.1 %) 5 (22.7 %) 1 (33.3 %) 2 (28.6 %) 9 (33.3 %) 2 (11.1 %)
Abbrevations: UA unilateral adnexectomy, UC unilateral cystectomy, UA + CC unilateral adnexectomy + contralateral cystectomy, BC bilateral cystectomy
N/A not applicable
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subsequent pregnancy rate of 48 % after fertility spar-
ing treatment. On the other hand, Silva EG group [15]
reported the exist of late recurrence in BOTs, which
showed that recurrence rate were 10 %, 19 %, 10 % and
5 % in 5 years, 10 years, 15 years and more than
15 years, respectively. These clinical characteristics
provide a good opportunity for younger patients with
BOTs to give birth after conservative treatments [16].
However, the invasive recurrence and disease-related
deaths did occur and the pregnancy rates varied greatly
among different studies. Emile Dara reported [17] the
subsequent pregnancy rates decreased to 34 % and the
risk of recurrence and lethal recurrence accordingly in-
creased to 38 % and 2 % in advanced stage BOTs.
Therefore, retrospective analyses of recurrence and
fertility related factors may help to develop better clin-
ical strategies for young women with BOTs, especially
when mentioned the specific fertility-sparing surgical
procedure.
Cystectomy is always supposed to preserve more nor-
mal ovarian tissue and therefore increase pregnancy
rates after conservative surgery. However the oncological
safety and true fertility benefits are still unknown. In our
study, we compared the recurrence rates and pregnancy
outcomes of four fertility-sparing surgeries (UA, UC,
UA + CC, and BC). Compared to UA group, the recur-
rence rate in cystectomy-included group increased from
2.1 % to 9.3 % and the relapse interval decreased from
48.0 months to 22.7 months. The tendency was even
clear in the BC group (22.2 %, 21.2 months). These data
aligned with the results from most published literatures.
As for patients with unilateral BOTs, the fertility rates
were satisfying in both UA and UC groups in our study
(76.9 % vs 77.3 %). Even in cases with bilateral BOTs,
the pregnancy outcomes were still encouraging in both
UA + CC and BC groups (71.4 % vs 66.7 %). But BC
group was accompanied by an enhanced recurrence rate
(22.2 % vs 14.3 %). However, there are different opinions
regarding the conservative treatment of bilateral BOTs.
Researchers [18] enrolled 32 young women with bilateral
BOTS in a randomized controlled study. And they found
that the cumulative pregnancy rate and the cumulative
probability of first pregnancy were significantly higher in
the BC group compared to UA + CC group (14/15 vs 9/
17; 5 months vs 8 months). However, no negative effects
were observed in the cumulative probability of first re-
currence in BC group (9/15 vs 10/17). A possible rea-
son for this finding may be that all 32 BOT patients in
that group underwent radical surgery in a short time
after fertility finished. Therefore, adnexectomy surgery
should be the first choice in unilateral BOT patients.
However, for patients with bilateral ovarian tumors or
with a history of previous ovarian surgery, UC or BC
could still be considered for those with a strong desire
for childbearing in short term, with the premise of fully
informed of easier relapse.
In recent years, laparoscopy was thought to be a minim-
ally invasive surgical procedure, which could better pro-
tect normal ovarian tissue and reduce pelvic adhesion.
These features satisfy the main objectivity of conservative
surgery. Thus, laparoscopy has been gradually preferred
by young patients with ovarian tumors. Researchers have
found that tumor rupture rate was higher in laparoscopy
group [19]. However, it has been inconclusive whether
high tumor rupture rate was an independent adverse
prognostic factor for recurrence. In some published stud-
ies, it was indicated that an increased tumor rupture rate
enhanced the recurrence rate after surgery [20]. However,
the conclusions were different in other researches.
Ødegaard E [21] retrospectively analyzed 107 patients
with BOTs. They observed that the rate of intra-operative
tumor rupture wasn’t significantly elevated during lapar-
oscopy if only when tumor diameter exceeded 10 cm, and
it did not have a negative impact on prognosis and preg-
nancy rate. Our study had drawn a similar conclusion
that, compared to laparotomy, laparoscopy had no disad-
vantage in terms of recurrence results. But it sharply
reduced the risk of infertility from 33.1 % to 11.1 % after
conservative surgery. All these researches indicated that
patients with short-term fertility plans could be recom-
mended for laparoscopy and pockets should be used to
extract the tumor tissues during surgery.
Though fertility-sparing surgery has been generally ac-
cepted as a treatment for young patients, there is less
agreement on staging surgery in BOTs. Trillsch F et al
[22] had evaluated the risk of staging procedures in 559
patients with serous BOTs. And they concluded that the
recurrence risk significantly increased if more than two
steps were skipped and the most crucial procedure was
omentectomy (HR 1.91). In some other reports, re-
searchers have also confirmed the association between
incomplete staging surgery and shorter recurrence inter-
vals [23]. However, even more researchers thought that
complete staging may elevate FIGO stage but provide no
benefit in reducing recurrence rate and improving over-
all survival [24]. Kristensen GS [25] had evaluated the
sensitivity and specificity of random biopsies, omentect-
omy, and hysterectomy; then he denied the benefits of
staging surgery in BOTs with a macroscopically normal
appearance. This finding were in accord with the studies
performed by Pirimoglu ZM [26] and we draw a similar
conclusion. In our observation, staging surgery had only
5 % (3/60) positive result, which increased the FIGO
stage but had no effects on recurrence. However, the
pregnancy rate was sharply decreased from 81.3 % to
53.8 % (p = 0.08). Because of the usual negative results of
staging surgery and the potential adverse impact on the
fertility, patients with apparent early stage BOTs were
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not always recommended for surgical staging in fertility
sparing surgery. Whether or not to take adjuvant chemo-
therapy in patients with BOTs has also been discussed for
a long time. Alexandra Leary [27] had reported on 36 pa-
tients with invasive implants serous BOTs and they were
treated with surgery and platinum-based chemotherapy.
Among these patients, 13 (36 %) relapsed, and eight
patients (22.2 %) progressed to invasive disease. However,
the 5-year progressive free survival (PFS) and overall
survival (OS) were improved, which were 67 % and 96 %
respectively. But there were some different observations in
our study. There were only 12 patients, who were at ad-
vanced stages or with invasive implants, received chemo-
therapy after surgery. The recurrence rate was 8.3 % and
the pregnancy rate was 75 %, which indicated that the
patients did not receive any benefit in recurrence and fer-
tility from chemotherapy. This finding was consistent with
some other published literatures [28, 29]. Ren J [30] had
studied 64 patients underwent postoperative chemother-
apy and concluded that there was no significant difference
in recurrence and overall survival rates. Even for patients
with invasive implants, some studies still had not demon-
strated any positive result [31]. So we would carefully
conclude that for BOT patients with a strong childbearing
desire, adjuvant chemotherapy should be avoided for the
shortest pregnancy planning period.
Conclusion
In conclusion, conservative surgery is relative safe and
beneficial for young women with BOTs who have a strong
desire for preserving their fertility ability. For most patients
with unilateral tumor, laparoscopic unilateral adnexectomy
should be the first choice because of its low recurrence rate
and high successful fertility rate. However, patients with
bilateral tumors, elevated CA125, extra-ovary tumor or
mucinous type are tended to recurrence in shorter interval,
conservative treatment should be carefully advised and
pregnancy should be achieved as soon as possible after
fertility sparing surgery. Moreover, Cystectomy-included
surgeries are still acceptable for patients with bilateral
BOTs or those who had undergone ovarian surgery before.
So far, there was no enough evidence to show benefit of
surgical staging in recurrence outcomes. But the invasive
staging procedures may lead to higher infertility rate. The
staging procedures often just advance the clinical stage, not
improve the prognosis. Most experts recommend less ag-
gressive surgery and comprehensive staging. Thus, surgical
staging is not always necessary in fertility sparing surgery,
especially for early stage BOTs. In addition, the benefits of
postoperative chemotherapy have not been demonstrated
for BOT patients without invasive implants, both in previ-
ous reports and our current study. This relatively large
group study demonstrated that fertility sparing surgery in
younger patients with BOTs is feasible. Long time follow
up, overall survival rate and impact to next generation
need to be further investigated in future. Overall, patients
with BOTs should be fully assessed by experienced
gynecological oncologist, and well informed about the
surgical risks and benefits before fertility sparing surgery.
What’s more, the patients should follow up closely and for
long term after conservative surgery.
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